|
GB0018891D0
(en)
*
|
2000-08-01 |
2000-09-20 |
Novartis Ag |
Organic compounds
|
|
US7189856B2
(en)
|
2001-12-28 |
2007-03-13 |
Gideon Shapiro |
Non-peptide somatostatin receptor ligands
|
|
GB0229020D0
(en)
*
|
2002-12-12 |
2003-01-15 |
Novartis Ag |
Organic compounds
|
|
BRPI0317176B1
(pt)
*
|
2002-12-12 |
2018-03-13 |
Novartis Ag |
Processo para a síntese de peptídeos contendo uma subestrutura de 4-hidróxi-prolina
|
|
GB0300095D0
(en)
*
|
2003-01-03 |
2003-02-05 |
Novartis Ag |
Organic compounds
|
|
GB0314695D0
(en)
*
|
2003-06-24 |
2003-07-30 |
Novartis Ag |
Organic compounds
|
|
PE20050285A1
(es)
|
2003-06-24 |
2005-06-09 |
Novartis Ag |
Composicion farmaceutica que comprende analogos ciclicos de somatostatina
|
|
GB0318682D0
(en)
|
2003-08-08 |
2003-09-10 |
Novartis Ag |
Organic compounds
|
|
EP1522311A1
(fr)
*
|
2003-10-10 |
2005-04-13 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Utilisation de la somatostine ou d'un de ses analogues pour préparer un médicament destiné à réguler la réserve folliculaire ovarienne chez la femme non ménopausée
|
|
MY158342A
(en)
|
2003-11-14 |
2016-09-30 |
Novartis Ag |
Pharmaceutical composition
|
|
GB0412866D0
(en)
*
|
2004-06-09 |
2004-07-14 |
Novartis Ag |
Organic compounds
|
|
GB0428151D0
(en)
|
2004-12-22 |
2005-01-26 |
Novartis Ag |
Organic compounds
|
|
GB0602639D0
(en)
*
|
2006-02-09 |
2006-03-22 |
Novartis Ag |
Organic compounds
|
|
AU2007255416A1
(en)
*
|
2006-06-08 |
2007-12-13 |
Novartis Ag |
Combination of somatostatin-analogs with dopamine- or growth hormone receptor antagonist
|
|
US7697338B2
(en)
*
|
2006-11-16 |
2010-04-13 |
Sandisk Corporation |
Systems for controlled boosting in non-volatile memory soft programming
|
|
WO2008064570A1
(en)
*
|
2006-11-28 |
2008-06-05 |
The University Of Hong Kong |
The use of granulin-epithelin precursor (gep) antibodies for detection and suppression of hepatocellular carcinoma (hcc)
|
|
EP1941902A1
(en)
*
|
2007-01-02 |
2008-07-09 |
Novartis AG |
Use of Somatostatin analogs in cluster headache
|
|
PT2118123E
(pt)
|
2007-01-31 |
2016-02-10 |
Harvard College |
Péptidos de p53 estabilizados e suas utilizações
|
|
JP5631201B2
(ja)
|
2007-03-28 |
2014-11-26 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ステッチングされたポリペプチド
|
|
PE20090387A1
(es)
|
2007-05-24 |
2009-04-28 |
Novartis Ag |
Formulacion de pasireotida
|
|
WO2009009035A1
(en)
*
|
2007-07-06 |
2009-01-15 |
Ipsen Pharma S.A.S. |
Somatostatin analog and uses thereof
|
|
GB0719818D0
(en)
*
|
2007-10-11 |
2007-11-21 |
Asterion Ltd |
Growth hormone fusion polypeptides
|
|
CA2705977C
(en)
*
|
2007-11-28 |
2016-06-14 |
Novartis Ag |
Use of somatostatin analogs in meningioma
|
|
SI2225271T1
(sl)
|
2007-12-03 |
2013-10-30 |
Italfarmaco S.P.A. |
Novi selektivni analogi somatostatina
|
|
EP2067786A1
(en)
|
2007-12-07 |
2009-06-10 |
ITALFARMACO S.p.A. |
Novel non selective analogs of somatostatin
|
|
US20090325863A1
(en)
*
|
2008-06-13 |
2009-12-31 |
Kleinberg David L |
Somatostatin analogs and IGF-I inhibition for breast cancer prevention
|
|
WO2010003939A1
(en)
*
|
2008-07-08 |
2010-01-14 |
Novartis Ag |
Use of pasireotide for the treatment of endogenous hyperinsulinemic hypoglycemia
|
|
EP2172189A1
(en)
|
2008-10-01 |
2010-04-07 |
Novartis AG |
Pharmaceutical Compositions
|
|
EP2213307A1
(en)
|
2009-02-03 |
2010-08-04 |
Novartis AG |
Injectable depot formulations
|
|
JP5623406B2
(ja)
|
2008-09-17 |
2014-11-12 |
キアズマ インコーポレイテッド |
医薬組成物および関連する送達方法
|
|
UY33236A
(es)
|
2010-02-25 |
2011-09-30 |
Novartis Ag |
Inhibidores dimericos de las iap
|
|
MX355543B
(es)
|
2010-08-13 |
2018-04-20 |
Aileron Therapeutics Inc Star |
Macrociclos peptidomiméticos.
|
|
WO2012074559A2
(en)
|
2010-12-02 |
2012-06-07 |
New York University |
Treatment of non-proliferative cystic disease
|
|
UY33794A
(es)
|
2010-12-13 |
2012-07-31 |
Novartis Ag |
Inhibidores diméricos de las iap
|
|
WO2012080260A1
(en)
|
2010-12-13 |
2012-06-21 |
Novartis Ag |
Dimeric iap inhibitors
|
|
US20130035054A1
(en)
*
|
2011-07-14 |
2013-02-07 |
Faceon Mobile |
Phone with multi-portal access for display during incoming and outgoing call
|
|
US8835123B2
(en)
|
2011-08-02 |
2014-09-16 |
New York University |
Methods for detecting progenitor cells and uses thereof
|
|
KR20140069235A
(ko)
|
2011-09-27 |
2014-06-09 |
노파르티스 아게 |
돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
|
|
TWI643868B
(zh)
|
2011-10-18 |
2018-12-11 |
艾利倫治療公司 |
擬肽巨環化合物
|
|
KR101979051B1
(ko)
|
2011-12-05 |
2019-05-15 |
카무러스 에이비 |
강력한 방출-조절된 제형
|
|
CN104105690A
(zh)
|
2011-12-05 |
2014-10-15 |
诺华股份有限公司 |
作为雄激素受体拮抗剂的环状尿素衍生物
|
|
HK1205758A1
(en)
|
2012-01-09 |
2015-12-24 |
Novartis Ag |
Rnai agents to treat beta-catenin related diseases
|
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
|
SG11201404648PA
(en)
|
2012-02-15 |
2014-09-26 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles
|
|
EP2819688A4
(en)
|
2012-02-15 |
2015-10-28 |
Aileron Therapeutics Inc |
PEPTIDOMIMETIC MACROCYCLES CROSS-LINKED WITH TRIAZOLE AND THIOETHER
|
|
IN2014DN09831A
(show.php)
*
|
2012-05-25 |
2015-08-07 |
Camurus Ab |
|
|
TWI633887B
(zh)
*
|
2012-05-31 |
2018-09-01 |
大塚製藥股份有限公司 |
用於預防及／或治療多囊性腎臟病之藥物
|
|
KR20150082307A
(ko)
|
2012-11-01 |
2015-07-15 |
에일러론 테라퓨틱스 인코포레이티드 |
이치환 아미노산 및 이의 제조 및 사용 방법
|
|
US9480759B2
(en)
|
2012-11-21 |
2016-11-01 |
Serene, Llc |
Tin-117m somatostatin receptor binding compounds and methods
|
|
CN105008343B
(zh)
|
2013-02-19 |
2017-12-08 |
诺华股份有限公司 |
作为选择性雌激素受体降解剂的苯并噻吩衍生物及其组合物
|
|
KR20150131224A
(ko)
|
2013-03-14 |
2015-11-24 |
노파르티스 아게 |
돌연변이 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
|
|
AU2014229283B2
(en)
|
2013-03-14 |
2016-07-28 |
Novartis Ag |
3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH
|
|
WO2014147586A1
(en)
|
2013-03-22 |
2014-09-25 |
Novartis Ag |
1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
|
|
CN103467575B
(zh)
*
|
2013-08-22 |
2016-03-02 |
深圳翰宇药业股份有限公司 |
一种帕西瑞肽的制备方法
|
|
CN103641894B
(zh)
*
|
2013-12-06 |
2015-10-28 |
深圳翰宇药业股份有限公司 |
一种治疗库欣病的多肽药物的制备方法
|
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
|
AU2014369213B2
(en)
|
2013-12-19 |
2017-10-19 |
Novartis Ag |
Drug delivery systems
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
JP6473457B2
(ja)
|
2014-01-17 |
2019-02-20 |
ノバルティス アーゲー |
Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
|
|
US10093646B2
(en)
|
2014-01-17 |
2018-10-09 |
Novartis Ag |
1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
|
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
|
LT3116909T
(lt)
|
2014-03-14 |
2020-02-10 |
Novartis Ag |
Antikūno molekulės prieš lag-3 ir jų panaudojimas
|
|
WO2015181624A2
(en)
|
2014-05-28 |
2015-12-03 |
Idenix Pharmaceuticals, Inc |
Nucleoside derivatives for the treatment of cancer
|
|
SG11201702223UA
(en)
|
2014-09-24 |
2017-04-27 |
Aileron Therapeutics Inc |
Peptidomimetic macrocycles and uses thereof
|
|
MA41044A
(fr)
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
|
EP3206711B1
(en)
|
2014-10-14 |
2023-05-31 |
Novartis AG |
Antibody molecules to pd-l1 and uses thereof
|
|
EP3226689B1
(en)
|
2014-12-05 |
2020-01-15 |
Merck Sharp & Dohme Corp. |
Novel tricyclic compounds as inhibitors of mutant idh enzymes
|
|
US10086000B2
(en)
|
2014-12-05 |
2018-10-02 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant IDH enzymes
|
|
US10442819B2
(en)
|
2014-12-05 |
2019-10-15 |
Merck Sharp & Dohme Corp. |
Tricyclic compounds as inhibitors of mutant IDH enzymes
|
|
HK1245115A1
(zh)
|
2014-12-10 |
2018-08-24 |
Amryt Endo, Inc. |
口腔奥曲肽与其他治疗剂联合应用
|
|
US20210317161A1
(en)
*
|
2014-12-19 |
2021-10-14 |
Auro Peptides Ltd |
A process for the preparation of pasireotide
|
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
|
EP3253401B1
(en)
|
2015-02-03 |
2025-04-02 |
Amryt Endo, Inc. |
Treating acromegaly with oral octreotide
|
|
PE20171448A1
(es)
|
2015-03-10 |
2017-10-02 |
Aduro Biotech Inc |
Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
|
|
KR20170129879A
(ko)
|
2015-03-20 |
2017-11-27 |
에일러론 테라퓨틱스 인코포레이티드 |
펩티드모방 거대고리 및 이의 용도
|
|
EP3280723B1
(en)
|
2015-04-08 |
2021-01-06 |
Polyphor AG |
Backbone-cyclized peptidomimetics
|
|
WO2016189055A1
(en)
|
2015-05-27 |
2016-12-01 |
Idenix Pharmaceuticals Llc |
Nucleotides for the treatment of cancer
|
|
EP3310779B1
(en)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Compounds and compositions for inhibiting the activity of shp2
|
|
ES2824576T3
(es)
|
2015-06-19 |
2021-05-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
|
CN107922388B
(zh)
|
2015-06-19 |
2020-12-29 |
诺华股份有限公司 |
用于抑制shp2活性的化合物和组合物
|
|
WO2016207912A1
(en)
*
|
2015-06-22 |
2016-12-29 |
Biophore India Pharmaceuticals Pvt. Ltd. |
Novel process for the preparation of pasireotide
|
|
GB201511790D0
(en)
|
2015-07-06 |
2015-08-19 |
Iomet Pharma Ltd |
Pharmaceutical compound
|
|
EP3317301B1
(en)
|
2015-07-29 |
2021-04-07 |
Novartis AG |
Combination therapies comprising antibody molecules to lag-3
|
|
CN114272371A
(zh)
|
2015-07-29 |
2022-04-05 |
诺华股份有限公司 |
包含抗pd-1抗体分子的联合疗法
|
|
WO2017019897A1
(en)
|
2015-07-29 |
2017-02-02 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
|
MX2018001814A
(es)
|
2015-08-13 |
2018-05-07 |
Merck Sharp & Dohme |
Compuestos dinucleotidos ciclicos como agonistas del estimulador de genes de interferon.
|
|
US11453697B1
(en)
|
2015-08-13 |
2022-09-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
CA3004138A1
(en)
|
2015-11-03 |
2017-05-11 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and tim-3 and their uses
|
|
US10538497B2
(en)
|
2015-12-15 |
2020-01-21 |
Merck Sharp & Dohme Corp. |
Compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
ES2986067T3
(es)
|
2015-12-17 |
2024-11-08 |
Novartis Ag |
Moléculas de anticuerpos frente a PD-1 y usos de las mismas
|
|
ES2849560T3
(es)
|
2016-05-04 |
2021-08-19 |
Genoscience Pharma Sas |
Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas
|
|
PT3468972T
(pt)
|
2016-06-14 |
2020-08-21 |
Novartis Ag |
Compostos e composições para inibir a atividade da shp2
|
|
WO2018009466A1
(en)
|
2016-07-05 |
2018-01-11 |
Aduro Biotech, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
|
GEP20217285B
(en)
|
2016-10-04 |
2021-08-10 |
Merck Sharp & Dohme |
BENZO[b]THIOPHENE COMPOUNDS AS STING AGONISTS
|
|
WO2018091542A1
(en)
|
2016-11-21 |
2018-05-24 |
Idenix Pharmaceuticals Llc |
Cyclic phosphate substituted nucleoside derivatives for the treatment of liver diseases
|
|
EP3573718B1
(en)
|
2017-01-27 |
2022-06-01 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
WO2018138684A1
(en)
|
2017-01-27 |
2018-08-02 |
Janssen Biotech, Inc. |
Cyclic dinucleotides as sting agonists
|
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
|
WO2018208667A1
(en)
|
2017-05-12 |
2018-11-15 |
Merck Sharp & Dohme Corp. |
Cyclic di-nucleotide compounds as sting agonists
|
|
US20200172628A1
(en)
|
2017-06-22 |
2020-06-04 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
|
US11285131B2
(en)
|
2017-08-04 |
2022-03-29 |
Merck Sharp & Dohme Corp. |
Benzo[b]thiophene STING agonists for cancer treatment
|
|
JP2020529421A
(ja)
|
2017-08-04 |
2020-10-08 |
メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． |
がんの処置のためのＰＤ−１アンタゴニストおよびベンゾ［ｂ］チオフェンＳＴＩＮＧアゴニストの組み合わせ
|
|
EP3681879A1
(en)
|
2017-09-11 |
2020-07-22 |
Krouzon Pharmaceuticals, Inc. |
Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2
|
|
WO2019067332A1
(en)
|
2017-09-27 |
2019-04-04 |
Merck Sharp & Dohme Corp. |
COMPOSITIONS AND METHODS FOR TREATING CANCER THROUGH A COMBINATION OF PROGRAMMED DEATH ANTIBODY ANTIBODIES (PD-1) AND A CXCR2 ANTAGONIST
|
|
US11180497B2
(en)
*
|
2017-10-18 |
2021-11-23 |
Angex Pharmaceutical, Inc. |
Cyclic compounds as immunomodulating agents
|
|
US12275729B2
(en)
|
2017-11-01 |
2025-04-15 |
Merck Sharp & Dohme Llc |
Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
|
|
CA3082108A1
(en)
|
2017-11-14 |
2019-05-23 |
Merck Sharp & Dohme Corp. |
Novel substituted biaryl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors
|
|
US11498904B2
(en)
|
2017-11-14 |
2022-11-15 |
Merck Sharp & Dohme Llc |
Substituted biaryl compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
|
|
JP7317014B2
(ja)
|
2017-12-15 |
2023-07-28 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｓｔｉｎｇアゴニストとしての環状ジヌクレオチド
|
|
US11685761B2
(en)
|
2017-12-20 |
2023-06-27 |
Merck Sharp & Dohme Llc |
Cyclic di-nucleotide compounds as sting agonists
|
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
|
WO2019177873A1
(en)
|
2018-03-13 |
2019-09-19 |
Merck Sharp & Dohme Corp. |
Arginase inhibitors and methods of use
|
|
JP7326319B2
(ja)
|
2018-04-03 |
2023-08-15 |
メルク・シャープ・アンド・ドーム・エルエルシー |
Ｓｔｉｎｇアゴニストとしてのベンゾチオフェン類及び関連する化合物
|
|
EP3774765A4
(en)
|
2018-04-03 |
2021-12-29 |
Merck Sharp & Dohme Corp. |
Aza-benzothiophene compounds as sting agonists
|
|
WO2019204179A1
(en)
|
2018-04-20 |
2019-10-24 |
Merck Sharp & Dohme Corp. |
Novel substituted rig-i agonists: compositions and methods thereof
|
|
UY38247A
(es)
|
2018-05-30 |
2019-12-31 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
|
US11352320B2
(en)
|
2018-05-31 |
2022-06-07 |
Merck Sharp & Dohme Corp. |
Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
US11274111B2
(en)
|
2018-06-20 |
2022-03-15 |
Merck Sharp & Dohme Corp. |
Arginase inhibitors and methods of use
|
|
US10596278B2
(en)
|
2018-07-25 |
2020-03-24 |
Advanced Accelerator Applications (Italy) S.R.L. |
Stable, concentrated radionuclide complex solutions
|
|
TW202517303A
(zh)
|
2018-07-25 |
2025-05-01 |
法商高級催化劑應用品有限公司 |
穩定的、濃縮的放射性核種錯合物溶液
|
|
US10596276B2
(en)
|
2018-07-25 |
2020-03-24 |
Advanced Accelerator Applications (Italy) S.R.L. |
Stable, concentrated radionuclide complex solutions
|
|
EP3853234B1
(en)
|
2018-09-18 |
2025-04-23 |
Nikang Therapeutics, Inc. |
Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors
|
|
EP3856349A1
(en)
|
2018-09-25 |
2021-08-04 |
Black Diamond Therapeutics, Inc. |
Tyrosine kinase inhibitor compositions, methods of making and methods of use
|
|
BR112021005513A2
(pt)
|
2018-09-25 |
2021-06-22 |
Black Diamond Therapeutics, Inc. |
derivados de quinazolina como inibidor de tirosina quinase, composições, métodos de fabricação e uso dos mesmos
|
|
US12138262B2
(en)
|
2018-09-29 |
2024-11-12 |
Novartis Ag |
Process of manufacture of a compound for inhibiting the activity of SHP2, as well as products resulting from acid addition
|
|
WO2020092183A1
(en)
|
2018-11-01 |
2020-05-07 |
Merck Sharp & Dohme Corp. |
Novel substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
WO2020096871A1
(en)
|
2018-11-06 |
2020-05-14 |
Merck Sharp & Dohme Corp. |
Novel substituted tricyclic compounds as indoleamine 2,3-dioxygenase inhibitors
|
|
US12264134B2
(en)
|
2018-11-28 |
2025-04-01 |
Merck Sharp & Dohme Llc |
Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
|
|
WO2020131598A1
(en)
|
2018-12-18 |
2020-06-25 |
Merck Sharp & Dohme Corp. |
Arginase inhibitors and methods of use
|
|
WO2020205688A1
(en)
|
2019-04-04 |
2020-10-08 |
Merck Sharp & Dohme Corp. |
Inhibitors of histone deacetylase-3 useful for the treatment of cancer, inflammation, neurodegeneration diseases and diabetes
|
|
WO2020260547A1
(en)
|
2019-06-27 |
2020-12-30 |
Rigontec Gmbh |
Design method for optimized rig-i ligands
|
|
US11155567B2
(en)
|
2019-08-02 |
2021-10-26 |
Mersana Therapeutics, Inc. |
Sting agonist compounds and methods of use
|
|
MX2022001952A
(es)
|
2019-08-15 |
2022-06-02 |
Black Diamond Therapeutics Inc |
Compuestos de alquinil quinazolina.
|
|
EP4031578A1
(en)
|
2019-09-18 |
2022-07-27 |
Novartis AG |
Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
|
|
EP4053124A1
(en)
|
2019-10-28 |
2022-09-07 |
Shanghai Institute of Materia Medica, Chinese Academy of Sciences |
Five-membered heterocyclic oxocarboxylic acid compound and medical use thereof
|
|
WO2021113679A1
(en)
|
2019-12-06 |
2021-06-10 |
Mersana Therapeutics, Inc. |
Dimeric compounds as sting agonists
|
|
WO2021126725A1
(en)
|
2019-12-17 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Novel substituted 1,3,8-triazaspiro[4,5]decane-2,4-dione compounds as indoleamine 2,3-dioxygenase (ido) and/or tryptophan 2,3-dioxygenase (tdo) inhibitors
|
|
US20230140132A1
(en)
|
2020-01-07 |
2023-05-04 |
Merck Sharp & Dohme Llc |
Arginase inhibitors and methods of use
|
|
WO2021195206A1
(en)
|
2020-03-24 |
2021-09-30 |
Black Diamond Therapeutics, Inc. |
Polymorphic forms and related uses
|
|
MY210304A
(en)
|
2020-04-02 |
2025-09-10 |
Mersana Therapeutics Inc |
Antibody drug conjugates comprising sting agonists
|
|
IL297781A
(en)
|
2020-05-06 |
2022-12-01 |
Merck Sharp & Dohme Llc |
il4i1 inhibitors and methods of use
|
|
EP4267575A1
(en)
|
2020-12-22 |
2023-11-01 |
Nikang Therapeutics, Inc. |
Compounds for degrading cyclin-dependent kinase 2 via ubiquitin proteosome pathway
|
|
US11141457B1
(en)
|
2020-12-28 |
2021-10-12 |
Amryt Endo, Inc. |
Oral octreotide therapy and contraceptive methods
|
|
EP4277901A1
(en)
|
2021-01-13 |
2023-11-22 |
Monte Rosa Therapeutics, Inc. |
Isoindolinone compounds
|
|
WO2022170052A1
(en)
|
2021-02-05 |
2022-08-11 |
Black Diamond Therapeutics, Inc. |
Quinazoline derivatives, pyridopyrimidine derivatives, pyrimidopyrimidine derivatives, and uses thereof
|
|
WO2022219407A1
(en)
|
2021-04-14 |
2022-10-20 |
Monte Rosa Therapeutics Ag |
Isoindolinone compounds
|
|
WO2022219412A1
(en)
|
2021-04-14 |
2022-10-20 |
Monte Rosa Therapeutics Ag |
Isoindolinone amide compounds useful to treat diseases associated with gspt1
|
|
WO2022227015A1
(en)
|
2021-04-30 |
2022-11-03 |
Merck Sharp & Dohme Corp. |
Il4i1 inhibitors and methods of use
|
|
TW202317589A
(zh)
|
2021-07-14 |
2023-05-01 |
美商尼坎醫療公司 |
作為ｋｒａｓ抑制劑的伸烷基衍生物
|
|
JP2025509886A
(ja)
|
2022-03-28 |
2025-04-11 |
ニカング セラピューティクス， インコーポレイテッド |
サイクリン依存性キナーゼ２阻害剤としてのスルホンアミド誘導体
|
|
WO2023240024A1
(en)
|
2022-06-08 |
2023-12-14 |
Nikang Therapeutics, Inc. |
Sulfamide derivatives as cyclin-dependent kinase 2 inhibitors
|
|
EP4580686A1
(en)
*
|
2022-08-30 |
2025-07-09 |
Grafton Therapeutics Sàrl |
Halogenated somatostatin analogs with multiple somatostatin receptor subtype selectivity
|
|
EP4615833A1
(en)
|
2022-11-11 |
2025-09-17 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|
|
TW202502311A
(zh)
|
2023-03-29 |
2025-01-16 |
美商默沙東有限責任公司 |
Il4i1抑制劑及其使用方法
|
|
WO2025072462A1
(en)
|
2023-09-27 |
2025-04-03 |
Nikang Therapeutics, Inc. |
Sulfonamide derivatives as cyclin-dependent kinase 2 inhibitors
|
|
TW202527955A
(zh)
|
2023-11-27 |
2025-07-16 |
美商尼坎醫療公司 |
用於經由泛素蛋白酶體途徑降解週期蛋白依賴性激酶２和週期蛋白依賴性激酶４的含有２，５－取代的嘧啶衍生物的雙功能化合物
|
|
WO2025117981A1
(en)
|
2023-12-02 |
2025-06-05 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway
|
|
WO2025212828A1
(en)
|
2024-04-03 |
2025-10-09 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|
|
WO2025240536A1
(en)
|
2024-05-15 |
2025-11-20 |
Nikang Therapeutics, Inc. |
Bifunctional compounds containing 2,5-substituted pyrimidine derivatives for degrading cyclin-dependent kinase 2 and/or cyclin-dependent kinase 4 via ubiquitin proteasome pathway
|